It is made available under a CC-BY-NC-ND 4.0 International license .

1	LinAge2: Providing actionable insights and benchmarking with
2	epigenetic clocks
3	
4	
5	
6	Sheng Fong <sup>1,2</sup> , Kirill A. Denisov <sup>3</sup> , Brian K. Kennedy <sup>4,5,6,7</sup> , Jan Gruber <sup>4,5,6*</sup>
7	
8	
9	
10	<sup>1</sup> Population Health Research Office, Ng Teng Fong General Hospital, Singapore
11	<sup>2</sup> Department of Medicine (Geriatric Medicine), Ng Teng Fong General Hospital, Singapore
12	<sup>3</sup> Gero PTE, Paya Lebar Square, Singapore
13	<sup>4</sup> Healthy Longevity Translational Research Program, Yong Loo Lin School of Medicine, National
14	University of Singapore, Singapore
15	<sup>5</sup> Center for Healthy Longevity, National University Health System, Singapore
16	<sup>6</sup> Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore,
17	Singapore
18	<sup>7</sup> Department of Physiology, Yong Loo Lin School of Medicine, National University of Singapore,
19	Singapore
20	
21	
22	* Corresponding author
23	Email: bchjg@nus.edu.sg (JG)

It is made available under a CC-BY-NC-ND 4.0 International license .

# 24 Abstract

Biological aging is marked by a decline in resilience at the cellular and systemic levels, driving an exponential increase in mortality risk. Here, we evaluate several clinical and epigenetic clocks for their ability to predict mortality, demonstrating that clocks trained on survival and functional aging outperform those trained on chronological age. We present an enhanced clinical clock that predicts mortality more accurately and provides actionable insights for guiding personalized interventions. These findings highlight the potential of mortality-predicting clocks to inform clinical decision-making and promote strategies for healthy longevity.

It is made available under a CC-BY-NC-ND 4.0 International license .

### 32 **Main**

33 Biological aging is characterized by the progressive decline in intrinsic biological resilience that is 34 associated with an exponential increase in mortality, expressed in the demographic "Gompertz 35 mortality law"<sup>1</sup>. Not all humans age at the same rate since genetics, lifestyle and stochastic factors 36 can affect future mortality and morbidity trajectories. Consequently, individual true biological age (BA) 37 is not identical to calendar or chronological age (CA). The true BA of an individual can be uniquely 38 defined as the age at which subjects of a reference cohort have the same risk of age-dependent 39 disease and all-cause mortality as the subject in question. Tools to accurately track changes in true 40 BA are essential for the development and validation of novel life- and healthspan-optimizing diet, 41 lifestyle, supplement and drug interventions.

42

43 Biological aging "clocks" are computational tools that estimate individual true BA based on 44 demographic, clinical, and/or molecular data. CA itself is widely used for both clinical prognostication 45 and decision-making, and can be viewed as a first order approximation of true BA. The ideal BA clock 46 should predict individual Gompertz mortality risk with higher accuracy than CA. Some aging clocks, 47 including most clinical clocks, explicitly include CA as a covariate, using biological features to estimate 48 a correction factor aimed at providing a better estimate of true BA. CA in this case is used as a proxy 49 for effects and mechanisms, such as entropic damage, not captured by the clock itself. Of course, the 50 ideal clock would include all relevant processes, wherein the model would assign zero or negligible 51 weight to CA.

52


53 Aging clocks are generalizations of current clinical risk markers that predict disease-specific morbidity 54 and, in some cases, mortality. Aging clocks should similarly enable early detection of hidden or 55 subclinical diseases, surpassing the capabilities of diagnostics by identifying disease processes years 56 or decades before overt disease is present. Secondly, to inform risk-to-benefit estimates (clinical 57 equipoise), aging clocks should capture all-cause mortality holistically, providing value beyond organ 58 or disease-specific risks. Thirdly, aging clocks must be sensitive to individual variations in biological 59 resilience. Finally, aging clocks should provide tools for mechanistic interpretation and provide 60 actionable insights, facilitating targeted interventions. To date, none of the existing clocks meet all 61 these criteria.

It is made available under a CC-BY-NC-ND 4.0 International license .

62

To evaluate the performance of aging clocks, we can compare them to a hypothetical "ideal" clock, which we term "CrystalAge". This optimal clock would predict disease-specific and all-cause mortality at the individual level with near-perfect accuracy, essentially forecasting an individual's date of death (Fig. 1a and d). While practically impossible, in retrospective studies, we can determine the theoretically optimal performance of CrystalAge and use it as a benchmark to evaluate the performance of existing aging clocks.

It is made available under a CC-BY-NC-ND 4.0 International license .



69 Ability to work (40-64 yo) Ability to perform all IADLs (65-84 yo) Ability to perform all bADLs (65-84 yo) 70 70 Fig. 1: LinAge2 predicts 20-year all-cause mortality and tracks with healthspan markers. a-c, 71 Kaplan-Meier survival curves showing 20-year survival in the 65-74 CA bin (n=631). For each clock, 72 subjects were stratified by selecting the lowest (best, solid line) and highest (worst, dotted line) 25% 73 quartiles for BA. Clocks within the same quartile were compared using log-rank tests with Benjamini-74 Hochberg correction. Areas shaded indicate 95% error bands for lines of the same color. b, 75 Compared to ChronAge, use of LinAge2 BA results in a significant survival difference for the lowest 76 25% BA quartile (P=6.16E-04), but not for the highest 25% quartile (P=0.07). PhenoAge Clinical did 76 not significantly outperform ChronAge in predicting survival in this age bin. c, LinAge2 significantly 78 outperformed DunedinPoAm (P=1.09E-02) and PhenoAge DNAm (P=1.37E-03) in the lowest 25% BA 79 quartile, but not GrimAge2 (P=0.22). In the highest 25% quartile, while LinAge2 significantly 80 outperformed PhenoAge DNAm (P=0.03), the differences between LinAge2 and DunedinPoAm

It is made available under a CC-BY-NC-ND 4.0 International license .

81 (P=0.11) and GrimAge2 (P=0.58) did not reach statistical significance. e, ROC analysis revealed that 82 LinAge2 (area under the curve (AUC)=0.8684) was significantly more informative than PhenoAge 83 Clinical (AUC=0.8479, P=6.35E-05) and ChronAge (AUC=0.8288, P=3.16E-10) in predicting future 84 mortality (n=2,036). LinAge2 performed similarly to LinAge (AUC=0.8647). f, LinAge2 also 85 outperformed PhenoAge DNAm (AUC=0.7859, P=4.44E-07) and GrimAge2 (AUC=0.8233, P=0.02) in 86 predicting 20-year mortality (n=1,065). Although GrimAge2 outperformed ChronAge (AUC=0.7933, 87 P=2.74E-03) in predicting 20-year mortality, PhenoAge DNAm did not (P=0.47). a,d, HorvathAge, 88 HannumAge, and ChronAge did not significantly differ in predicting mortality risk (AUCs=0.7776, 89 0.7978 and 0.7933, respectively, n=1,065). ROC curves were compared using DeLong's test. 90 a,b,d,e,f, CrystalAge, a theoretical perfect clock shown for reference, accurately identifies individuals 91 at risk of dying (AUC=1), whereas RandomAge adds random gaussian noise of ±10 years to CA. g-k, 92 Violin plots for each clock categorized into low (biologically younger/best 25% quartile) and high 93 (biologically older/worst 25% quartile) groups plotted against healthspan markers: cognitive scores 94 (digit symbol substitution test), gait speed, ability to work, and ability to perform all instrumental and 95 basic activities of daily living (iADLs and bADLs). Groups (BA high versus low) were compared using 96 two-sided t-tests. Median value, lower (25<sup>th</sup>) and upper (75<sup>th</sup>) percentiles are indicated. Lines extend 97 to ±1.5 times interquartile range, with points outside this range drawn individually. The violin shape 98 indicates the probability density function. yo, years old. HA, HorvathAge. LA2, LinAge2. GA2, 99 GrimAge2. DPA, DunedinPoAm. 100

101 Taking inspiration from Levine's PhenoAge clinical clock<sup>2</sup>, we recently developed and validated clinical 102 aging clocks (PCAge, LinAge) based on linear dimensionality reduction by matrix factorization 103 (singular value decomposition) and demonstrated them to be highly predictive in terms of future 104 disease-specific and all-cause mortality<sup>3</sup>. These clocks have since been applied in a range of clinical 105 settings and, taking advantage of user feedback, we have implemented several improvements, 106 creating an updated version of these clocks (LinAge2). Like LinAge, we trained LinAge2 in the 107 National Health and Nutrition Examination Survey (NHANES) IV 1999-2000 wave before testing it in 108 the 2001-2002 wave. LinAge2 further reduces the number of rarely measured parameters and 109 emphasizes interpretability. For a detailed description of LinAge2's features and construction, refer to 110 Methods.

111

112 Many aging clocks have been developed, with epigenetic or DNA methylation (DNAm) clocks most 113 widely recognized and well-established. Several epigenetic clocks have been commercially licensed 114 for applications, including estimating CA (HorvathAge<sup>4</sup>, HannumAge<sup>5</sup>), optimizing life insurance 115 policies (PhenoAge DNAm<sup>6</sup>, GrimAge<sup>7</sup>), and monitoring the rate of aging (DunedinPoAm<sup>8</sup>)<sup>9</sup>. Recently, 116 a dataset of pre-calculated epigenetic clock ages has been published for the NHANES 1999-2002 117 waves, permitting direct comparison of the predictive power of CA, the original LinAge, LinAge2 and PhenoAge clinical clocks, and the HorvathAge, HannumAge, PhenoAge DNAm, GrimAge2<sup>10</sup> and 118 119 DunedinPoAm epigenetic clocks.

It is made available under a CC-BY-NC-ND 4.0 International license .

121 To compare efficacy in predicting mortality, we performed survival and receiver operating 122 characteristic (ROC) analyses on 20- and 10-year mortality in the NHANES 2001-2002 test cohort. 123 Compared to CA, LinAge2 demonstrated significant survival differences across all age bins, whereas 124 PhenoAge Clinical did not (Fig. 1b, Extended Data Fig. 1b and e). LinAge2 performed similarly to 125 LinAge and demonstrated superior predictive power for future mortality compared to PhenoAge 126 Clinical and CA (Fig. 1e and Extended Data Fig. 2b). Surprisingly, LinAge2 also outperformed 127 PhenoAge DNAm and DunedinPoAm in predicting age-specific survival differences (Fig. 1c, Extended 128 Data Fig. 1c and f) and future mortality (Fig. 1f and Extended Data Fig. 2c). In contrast, PhenoAge 129 DNAm, HorvathAge, and HannumAge did not significantly differ from CA in predicting future mortality 130 (Fig. 1a, d and f, Extended Data Fig. 1a and d, and Extended Data Fig. 2a and c). LinAge2 and 131 GrimAge2 performed similarly in predicting future mortality (Fig. 1f and Extended Data Fig. 2c) and 132 survival across all age bins (Fig. 1c, Extended Data Fig. 1c and f).

133


134 While mortality prediction is an important function of aging clocks, it is important to evaluate if clock 135 ages are similarly predictive of functional status and healthspan. We tested this for the same clinical 136 and epigenetic clocks by comparing markers of functional and health status in individuals selected by 137 each clock to be in the lowest 25% BA guartile (biologically younger, low) with those in the highest 138 25% quartile (biologically older, high). Our analysis revealed that LinAge2 low was associated with 139 superior healthspan markers, including higher cognitive scores, faster gait speed, ability to work, and 140 performance of all instrumental and basic activities of daily living (iADLs and bADLs) (Fig. 1g-k). 141 Conversely, individuals in the LinAge2 high group had poorer healthspan, with statistically significant 142 differences between the two groups across all markers (Fig. 1g-k). Similar trends were observed for 143 GrimAge2 and DunedinPoAm, with statistically significant differences between the low and high 144 groups across most healthspan markers, except for the ability to perform all bADLs (Fig. 1g-k and 145 Extended Data Fig. 3). In contrast, no statistically significant differences were found between 146 HorvathAge low and HorvathAge high across healthspan markers (Fig. 1g-k). Our findings on 147 healthspan markers and mortality, for HorvathAge, HannumAge, PhenoAge DNAm and GrimAge2, 148 corroborate similar findings for 10-year survival in 490 subjects of the Irish Longitudinal Study on 149 Aging<sup>11</sup>.

150

It is made available under a CC-BY-NC-ND 4.0 International license .

151 A significant drawback of many existing aging clocks is that they lack interpretability and actionable 152 insights, making it challenging to develop targeted interventions. However, one key benefit of clinical 153 clocks is that they are built from parameters directly related to the underlying disease mechanisms, 154 enabling easier interpretation of clock residuals and providing actionable insights into disease 155 pathophysiology. Individual age-associated principal components (PCs) identify clusters of features 156 that change in a coordinated manner during aging. Analyzing individual PCs can provide valuable 157 insights into the underlying patterns and trajectories of aging-related changes. Using heatmaps, we 158 visualized the predictive power of individual PCs relative to clinical outcomes, including sex-specific 159 causes of death and chronic diseases (Fig. 2). Supplementary Table 5 provides detailed insights into 160 the interpretation of each PC, including associations with causes of death, chronic diseases, lifestyle 161 factors, and potential aging mechanisms, as well as suggested interventions to optimize each PC and 162 lower BA.

#### It is made available under a CC-BY-NC-ND 4.0 International license .



163 164 Fig. 2: Heatmaps illustrating the associations between clinical outcomes and PCs analyzed 165 using multivariate logistic regression. Associations of PCs with specific causes of death at a-b, 10-166 20 year and c-d, 0-5 year follow-up for male and females, respectively. Strength of association (odds 167 ratio) is represented using a red color scale. PCs that are strongly positively associated with a specific 168 cause of death are bright red. For cause of death, negative associations were truncated by setting 169 their values to zero (i.e. no harm). e-f, Association of PCs with specific chronic diseases, and 170 measures of lifestyle and socioeconomic status. Strength of association is represented using a blue-171 red scale ranging from -1 (blue, negative association) to 2 (red, positive association). PCs that are 172 strongly positively associated (positive risk ratios) with a specific disease are bright red, whereas PCs 173 that are strongly negatively associated (negative risk ratios) with a specific disease are bright blue.

174

175 Accurately predicting patient outcomes and allocating healthcare resources is a significant challenge

176 in clinical practice<sup>12</sup>. Currently, clinicians rely heavily on CA to make these decisions. However, here

It is made available under a CC-BY-NC-ND 4.0 International license .

177 we show that mortality-predicting clocks, such as LinAge2 and GrimAge2, outperform CA in predicting 178 mortality risk across timeframes, ranging from 2-20 years (Fig. 1, Extended Data Fig. 4). Moreover, 179 clinical clocks can also predict specific causes of death within a 5-year window (Fig. 2c and d). This 180 illustrates that clock-based BAs are more accurate and informative estimates of true BA than CA itself. 181 By providing a more precise metric of biological status than CA alone, BA can enable clinicians to 182 better support patients and their caregivers in navigating healthcare choices, including end-of-life 183 care.

184

185 Overall, our analysis reveals that, regardless of feature space (methylation or clinical), aging clocks 186 trained to predict mortality or functional aging outcomes provide more predictive value in terms of 187 clinical decision-making. Surprisingly, clinical aging clocks still outperform several prominent mortality-188 predicting and functional epigenetic clocks, including PhenoAge DNAm and DunedinPoAm, in 189 predicting future mortality. A key advantage of LinAge2 lies in its interpretability. Because principal 190 component analysis is a linear matrix factorization technique, the resulting model is easier to interpret 191 than nonlinear alternatives<sup>13</sup>. Latent variables based on linear dimensionality reduction (PCs), 192 especially those based on clinical parameters, are comparatively easy to understand and interpret, 193 making them more actionable. This enables clinical aging clocks like LinAge2 to detect hidden or 194 subclinical diseases and inform primordial prevention strategies. By identifying individuals at high risk 195 of developing specific diseases, healthcare providers can implement targeted interventions early and 196 proactively. By casting specific risk in terms of BA acceleration, aging clocks can significantly increase 197 compliance and adherence with specific health recommendations<sup>14</sup>. For example, male smokers with 198 high PC5M values in LinAge2 are at increased risk of death from chronic lung disease and should be 199 screened and advised to quit smoking (Fig. 2 and Supplementary Table 5).

200

All current aging clocks, regardless of feature space (e.g. clinical, methylation, proteomics, etc.) and target (mortality, functional outcomes, disease, or CA) share significant limitations. Most importantly, many current clocks employ linear techniques (e.g. principal component analysis/singular value decomposition, regression-based predictions), which limit their ability to distinguish between aging signatures and those of age-dependent diseases, and to learn U-shape response patterns. Current clocks therefore inherently conflate intrinsic biological aging with disease-specific signatures (hidden

It is made available under a CC-BY-NC-ND 4.0 International license .

207 sickness, primordial disease signatures). Nonlinear approaches including generative artificial 208 intelligence and artificial neural networks are being investigated and could offer improved models, but 209 their increased complexity pose a significant challenge for interpretation<sup>15,16</sup>. Next generation clocks 210 will need to differentiate between disease signatures and intrinsic aging, and quantify intrinsic 211 biological resilience. Further theoretical work will be required to deconvolute these disease-centric 212 signatures from determinants of intrinsic resilience and entropic aging<sup>17-19</sup>. Advancing next generation 213 clocks is crucial to equip healthcare providers with the essential tools needed to make informed 214 decisions regarding targeted interventions that support healthy longevity in populations where 215 healthcare needs are increasingly dominated by aging.

It is made available under a CC-BY-NC-ND 4.0 International license .

### 216 Methods

# 217 Motivation for enhancing LinAge2

218 The original PCAge and LinAge<sup>3</sup> both utilized some parameters that are not routinely collected. 219 LinAge has been utilized by several clinics worldwide, and we have received informal feedback 220 regarding its use. Common suggestions for enhancing the clock include: (i) improving handling of 221 outliers and threshold effects, (ii) further refining the clinical parameters, especially removing serum 222 fibrinogen due to the need for a specialized sodium citrate tube, (iii) providing additional tools to 223 improve the interpretability of PCs, and (iv) providing specific strategies to optimize each PC to lower 224 BA. PCs can also be sensitive to outliers, thresholding and batch effects. We developed LinAge2 in 225 response to these concerns.

226

227 We followed the same workflow, as previously described<sup>3</sup>, to construct LinAge2 but with several 228 modifications. To enhance LinAge2, we refined the clinical parameters by reducing the total number to 229 60, removing serum fibrinogen (Supplementary Table 2). We also addressed outliers and thresholding 230 by capping outliers at six standard deviations and log-transforming additional parameters 231 (Supplementary Table 2). Batch effects were mitigated through z-score normalization by median and 232 median absolute deviation to a younger, generally healthy cohort (age 40-50 years), separately for 233 males and females (Supplementary Table 2), generating sex-specific PCs. The loadings for male and 234 female PCs are provided in Supplementary Table 3, and sex-specific weights of the Cox proportional 235 hazards models are listed in Supplementary Table 4.

236

A parametrized version of LinAge2 is provided as previously described<sup>3</sup> (Supplementary Table 2). The
 baseline characteristics of the study participants are listed in Supplementary Table 1.

239

### 240 PhenoAge Clinical and epigenetic clocks

PhenoAge Clinical was implemented using the equation from the original publication. The dataset of pre-calculated epigenetic clock ages published for the NHANES 1999-2002 waves were obtained from https://wwwn.cdc.gov/nchs/nhanes/dnam/ and analyzed.

It is made available under a CC-BY-NC-ND 4.0 International license .

#### 245 **Construction of healthspan markers**

246 The digit symbol substitution test score (NHANES variable 'CFDRIGHT') was used as a cognitive 247 measure. Gait speeds were obtained by taking the total distance walked (20 feet or 6.096 meters) 248 divided by the time taken (NHANES variable 'MSXWTIME'). Differences in cognitive scores and gait 249 speeds were calculated as the percent difference between a control group (middle 50% of all 250 subjects), for younger (best 25% quartile) and older (worst 25% quartile) groups. The ability to work 251 was established using the NHANES variable 'PFQ048'. The ability to perform all instrumental 252 activities of daily living (iADLs) was a combination of the NHANES variables 'PFQ060A', 'PFQ060F', 253 'PFQ060G', 'PFQ060Q', PFQ060R' and 'PFQ060S', while the ability to perform all basic activities of 254 daily living (bADLs) was a combination of the NHANES variables 'PFQ060B', 'PFQ060C', 'PFQ060H', 255 'PFQ060I', 'PFQ060J', 'PFQ060K' and 'PFQ060L'. Participants had to have either no difficulty or 256 some difficulty in all the variables to be deemed able to perform all iADLs or all bADLs.

257

### 258 Heatmap analysis

Using the 'nnet'<sup>20</sup> (version 7.3-19) R package, heatmaps were generated to evaluate the predictive values for PCs included in LinAge2. For each parameter, we attempted to predict status (diseased/compromised or not) using multivariate logistic regression with the clock PCs as covariates. PCs that received a statistically insignificant ( $P \ge 0.05$ ) weight in the logistic regression model were assigned zero weights (white). The remaining PCs (P < 0.05) were assigned color values according to their weight in the model (see Fig. 2f legend for color mapping).

265

### 266 Statistics and reproducibility

For the NHANES IV 1999-2002 waves, we excluded: participants top-coded at age 85 years, as we could not ascertain the exact CAs of these adults, and participants who died from accidental deaths, as these were deemed to be not age-related.

270

271 Survival analyses were performed using log-rank tests with Benjamini-Hochberg correction. ROC 272 curves were compared using DeLong's test. For healthspan markers, two-sided t-tests were used to 273 compare between the low and high clock groups. All statistical analyses were performed using R 274 version 4.2.0 (https://www.R-project.org/).

It is made available under a CC-BY-NC-ND 4.0 International license .

#### 275

# 276 Data availability

- 277 All datasets used are publicly available online at https://wwwn.cdc.gov/nchs/nhanes/Default.aspx.
- 278 There were no restrictions on data availability. This study was reported according to STROBE
- 279 guidelines for cohort studies.
- 280

# 281 **References**

- 282 1 Gompertz, B. On the nature of the function expressive of the law of human mortality : and on a new mode of determining the value of life contingencies ; In a letter to Francis Baily / by Benjamin Gompertz. (Printed by W. Nicol, 1825).
- Fong, S. *et al.* Principal component-based clinical aging clocks identify signatures of healthy aging and targets for clinical intervention. *Nat Aging* 4, 1137-1152 (2024).
   https://doi.org:10.1038/s43587-024-00646-8
- 4 Horvath, S. DNA methylation age of human tissues and cell types. *Genome Biol* 14, R115 (2013). <a href="https://doi.org/10.1186/gb-2013-14-10-r115">https://doi.org/10.1186/gb-2013-14-10-r115</a>
- 2935Hannum, G. et al. Genome-wide methylation profiles reveal quantitative views of human<br/>aging rates. Mol Cell 49, 359-367 (2013). <a href="https://doi.org:10.1016/j.molcel.2012.10.016">https://doi.org:10.1016/j.molcel.2012.10.016</a>
- 2956Levine, M. E. et al. An epigenetic biomarker of aging for lifespan and healthspan. Aging<br/>(Albany NY) 10, 573-591 (2018). <a href="https://doi.org:10.18632/aging.101414">https://doi.org:10.18632/aging.101414</a>
- 2977Lu, A. T. *et al.* DNA methylation GrimAge strongly predicts lifespan and healthspan. Aging298(Albany NY) 11, 303-327 (2019). <a href="https://doi.org:10.18632/aging.101684">https://doi.org:10.18632/aging.101684</a>
- Belsky, D. W. *et al.* Quantification of the pace of biological aging in humans through a blood test, the DunedinPoAm DNA methylation algorithm. *Elife* 9 (2020).
   https://doi.org:10.7554/eLife.54870
- 3029Moqri, M. et al. Biomarkers of aging for the identification and evaluation of longevity303interventions. Cell 186, 3758-3775 (2023). <a href="https://doi.org:10.1016/j.cell.2023.08.003">https://doi.org:10.1016/j.cell.2023.08.003</a>
- 304
   10
   Lu, A. T. et al. DNA methylation GrimAge version 2. Aging (Albany NY) 14, 9484-9549 (2022).

   305
   https://doi.org:10.18632/aging.204434
- 30611McCrory, C. et al. GrimAge Outperforms Other Epigenetic Clocks in the Prediction of Age-307Related Clinical Phenotypes and All-Cause Mortality. J Gerontol A Biol Sci Med Sci 76, 741-308749 (2021). https://doi.org:10.1093/gerona/glaa286
- Orlovic, M. *et al.* Accuracy of clinical predictions of prognosis at the end-of-life: evidence from routinely collected data in urgent care records. *BMC Palliat Care* 22, 51 (2023).
   https://doi.org:10.1186/s12904-023-01155-y
- 312 13 Sayed, N. *et al.* An inflammatory aging clock (iAge) based on deep learning tracks multimorbidity, immunosenescence, frailty and cardiovascular aging. *Nat Aging* 1, 598-615 (2021). <u>https://doi.org:10.1038/s43587-021-00082-y</u>
- 315 14 Bonner, C. *et al.* Interventions Using Heart Age for Cardiovascular Disease Risk
   316 Communication: Systematic Review of Psychological, Behavioral, and Clinical Effects. *JMIR* 317 Cardio 5, e31056 (2021). <u>https://doi.org:10.2196/31056</u>
- 31815Qiu, W., Chen, H., Kaeberlein, M. & Lee, S. I. ExplaiNAble BioLogical Age (ENABL Age): an<br/>artificial intelligence framework for interpretable biological age. Lancet Healthy Longev 4,<br/>e711-e723 (2023). <a href="https://doi.org/10.1016/S2666-7568(23)00189-7">https://doi.org/10.1016/S2666-7568(23)00189-7</a>
- 32116Nusinovici, S. et al. Application of a deep-learning marker for morbidity and mortality322prediction derived from retinal photographs: a cohort development and validation study.323Lancet Healthy Longev 5, 100593 (2024). <a href="https://doi.org/10.1016/S2666-7568(24)00089-8">https://doi.org/10.1016/S2666-7568(24)00089-8</a>
- 32417Denisov, K. A., Gruber, J. & Fedichev, P. O. Discovery of Thermodynamic Control Variables325that Independently Regulate Healthspan and Maximum Lifespan. *bioRxiv*,3262024.2012.2001.626230 (2024). <a href="https://doi.org:10.1101/2024.12.01.626230">https://doi.org:10.1101/2024.12.01.626230</a>

It is made available under a CC-BY-NC-ND 4.0 International license .

327 18 Perevoshchikova, K. & Fedichev, P. O. Differential Responses of Dynamic and Entropic Aging 328 bioRxiv, 2024.2002.2025.581928 Factors to Longevity Interventions. (2024). 329 https://doi.org:10.1101/2024.02.25.581928 330 Tarkhov, A. E., Denisov, K. A. & Fedichev, P. O. Aging clocks, entropy, and the challenge of 19 331 age reversal. AgingBio 2, e20240031 (2024). https://doi.org:10.59368/agingbio.20240031 332 20 Venables, W. N. & Ripley, B. D. Modern Applied Statistics with S. Fourth edn, (Springer, 333 2002). 334

# 335 Acknowledgements

- 336 We thank the National Health and Nutrition Examination Survey participants and staff who made this
- 337 study possible. We thank C. Chen for her careful reading of this manuscript. This research was
- 338 funded by the Ministry of Education in Singapore, grant numbers IG21-SG007 and A-0007215-00-00,
- to J.G. S.F. is supported by the Research Training Fellowship (MOH-001294-00) from the National
- 340 Medical Research Council Singapore. This work was supported by the Lien Foundation.

341

# 342 Author contributions


- 343 S.F., B.K.K. and J.G. conceived, conceptualized and designed the study. S.F., K.A.D. and J.G.
- analyzed and interpreted the data. S.F., B.K.K. and J.G. wrote the first draft of the paper.

345


## 346 **Competing interests**

347 The authors declare no competing interests.

It is made available under a CC-BY-NC-ND 4.0 International license .



## 348 Additional information




**b** 1.00 C 1.00 a 1.00 0.75 0.75 0.75 Sensitivity Sensitivity Sensitivity 0.50 0.50 0.50 10-vear mortality 10-year n 0.25 0.25 0.25 0.00 0.00 0.00 1.00 0.50 0.25 0.00 1.00 0.75 0.50 0.25 0.00 1.00 0.75 0.50 0.25 0.00 0.75 Specificity Specificity Specificity


**Extended Data Fig. 2: ROC curves for 10-year all-cause mortality in the test cohort. a,** There were no significant differences in the AUCs between HorvathAge (AUC=0.7425), HannumAge (AUC=0.7612), and ChronAge (AUC=0.7501) (n=1,065). **b**, LinAge2 (AUC=0.8468) was significantly more informative than PhenoAge Clinical (AUC=0.8203, P=6.91E-05) and ChronAge (AUC=0.7946, P=2.65E-09) in predicting future mortality (n=2,036). LinAge2 performed similarly to LinAge (AUC=0.8383). **c**, Compared to LinAge2 (AUC=0.8144), PhenoAge DNAm (AUC=0.7390, P=2.84E-

373 06) and GrimAge2 (AUC=0.7801, P=1.81E-03) were significantly less predictive of 10-year follow-up
 374 (*n*=1,065). Although GrimAge2 outperformed ChronAge (AUC=0.7501, P=0.01) in predicting 10-year
 375 mortality, PhenoAge DNAm did not (P=0.39). ROC curves were compared using DeLong's test.

376



377Ability to work (40-64 yo)Ability to perform all IADLs (65-84 yo)Ability to perform all bADLs (65-84 yo)378Extended Data Fig. 3: DunedinPoAm tracks with healthspan markers. Differences between379DunedinPoAm low (slow aging) and DunedinPoAm high (fast aging) were significant for: **a**, ability to380work; **b**, ability to perform instrumental activities of daily living (iADLs); but not for **c**, ability to perform381basic activities of daily living (bADLs). Median value, lower (25<sup>th</sup>) and upper (75<sup>th</sup>) percentiles are382indicated. Lines extend to ±1.5 times interquartile range, with points outside this range drawn383individually. The violin shape indicates the probability density function.



385 Specificity
386 Extended Data Fig. 4: Clinical clocks are better predictors of 2-year mortality than CA. ROC
387 curves for 2-year all-cause mortality in the test cohort. LinAge2 (AUC=0.8294, *P*=4.02E-06), LinAge
388 (AUC=0.8003, *P*=3.91E-04) and PhenoAge Clinical (AUC=0.7870, *P*=3.24E-03) were significantly
389 more predictive of 2-year follow-up than ChronAge (AUC=0.7120) (*n*=2,036). ROC curves were
390 compared using DeLong's test.